Alnylam Pharmaceuticals, Inc. vs Moderna, Inc.
A head-to-head of Alnylam Pharmaceuticals, Inc. (ALNY) and Moderna, Inc. (MRNA) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ALNY | MRNA |
|---|---|---|
| Market Cap | $41.87B | $19.47B |
| P/E (TTM) | 79.94 | — |
| Forward P/E | 21.24 | -10.81 |
| P/S | 9.77 | 8.44 |
| P/B | 36.31 | 2.61 |
| EV/EBITDA | 44.53 | -6.46 |
| Dividend Yield | — | — |
| Profit Margin | 13.46% | -144.92% |
| Gross Margin | 81.64% | 54.84% |
| Operating Margin | 13.51% | -159.94% |
| Revenue Growth (YoY) | +96.43% | +263.55% |
| FCF Yield | 1.54% | -8.54% |
| Debt / Equity | 93.86 | 7.96 |
| Current Ratio | 3.13 | 2.41 |
Share:
Compare Alnylam Pharmaceuticals, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.